Health Care · Pharmaceutical Preparations

RNAC Cartesian Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 145368799 filings
Russell 2000

RNAC at a glance

Cartesian Therapeutics, Inc. (RNAC, SEC CIK 1453687) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as April 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Cartesian Therapeutics, Inc. (RNAC) reported revenue of $400,000 (down 99.0% from FY2024) and a net loss of $130.3 million. Diluted EPS was -$5.02.
  • As of September 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Cartesian Therapeutics, Inc. (RNAC) shares worth $21.9 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Miljkovic Milos on January 6, 2026 of 3,573 shares at $6.82 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$400K
−99.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
21 funds
$21.9M · +0 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Late clinical-stage biopharma pioneering outpatient mRNA-engineered autologous cell therapies for autoimmune diseases targeting B-cell maturation antigen (BCMA)
  • New emphasis: Expansion of Descartes-08 into myositis (dermatomyositis, antisynthetase syndrome) with FDA IND accepted December 2025, Phase 2 trial to start H1 2026
  • Strategic shift: Prioritization of Descartes-08 development after pausing Descartes-08 in SLE and halting Descartes-15 for multiple myeloma to focus on MG and myositis
  • Quantitative highlight: Over 100 patients treated with Descartes-08 outpatient through Phase 1/2 trials; Phase 3 AURORA trial launched May 2025 targeting 100 MG patients
  • Noteworthy: FDA granted Orphan Drug, RMAT, and Rare Pediatric Disease Designations for Descartes-08; first mRNA CAR-T with no CRS, neurotoxicity, or genomic integration risks reported

Risk Factors

  • FDA investigation of T-cell malignancy risk for CAR-T therapies including Descartes-08, with potential for boxed warnings or REMS requirements in 2024-2025
  • Geopolitical conflict risks delaying patient enrollment in clinical trials, impacting multinational trial sites and timelines
  • Supply chain vulnerability due to reliance on third-party manufacturers for patient-specific mRNA CAR-T product candidates
  • Competition from DNA-based CAR-T therapies with established FDA approvals and safety track records
  • Cash burn risks from clinical trial delays and increased development costs, with potential premature trial termination impacting financial condition

Management Discussion & Analysis

  • Revenue $2.8M in 2025 vs $38.9M in 2024, collaboration and license revenue down $37.9M primarily from Sobi License milestone
  • Operating expenses $146.2M in 2025 vs $82.8M in 2024, R&D up 29% to $58.0M, G&A slightly up 4% to $31.5M
  • Operating loss $(143.4)M in 2025 vs $(43.9)M in 2024; net loss $(130.3)M vs $(77.4)M, loss increased 68%
  • Best segment: Grant revenue $2.4M in 2025, up $1.8M; worst segment: collaboration/license revenue down 99% to $0.4M
  • Cash $126.9M at year-end; $60.25M raised via Series A Preferred in 2023 Private Placement; no product sales yet
  • Management expects continued significant R&D, operating losses, and reliance on equity/debt financings; revenue from product sales not expected for several years

AI summary of the RNAC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New dilution risk: equity issuance or Loan Agreement conversions could reduce ownership and depress common-stock price
  • New debt-covenant risk: May 2026 K2HV Loan Agreement secured substantially all assets, excluding intellectual property
  • Liquidity risk: minimum unrestricted cash requirement equals 80% of lender obligations beginning April 1, 2027
  • Commercial risk: $40.0 million trailing three-month net product revenue covenant begins January 1, 2029
  • Default risk: K2HV may accelerate obligations after an event of default, potentially exceeding available cash

Management Discussion & Analysis

  • Quarterly revenue $0 vs $0.5M, down 100% YoY, reflecting no grant revenue
  • Net loss $11.5M vs $35.9M, operating loss $25.0M vs $21.1M YoY
  • R&D $15.6M, up $1.8M, led by Descartes-08 MG at $6.5M vs $5.4M
  • Cash, equivalents and restricted cash $124.7M, operating cash use $70.9M for nine months
  • Financing provided $69.6M, including $46.0M term-loan proceeds and $22.8M ATM proceeds
  • Outlook: continued losses and higher R&D spending, funding runway at least 12 months, additional financing required

AI summary of the RNAC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 net loss $11.5M, or $0.38 per share, versus $35.9M, or $1.38, in Q3 2025
  • Cash $124.7M, including $50M K2HV financing, expected to fund operations into 2028
Filed Sep 29, 2026Full analysis →

Item 8.01: Other Events

  • Five MG patients retreated after symptom recurrence at median 16.6 months following initial Descartes-08 treatment
  • Month 12 post-retreatment outcomes: MG-ADL reduction 6.6 points and MGC reduction 15 points from baseline

Item 7.01: Regulation FD Disclosure

  • Phase 2 Descartes-08 retreatment data update in myasthenia gravis
  • Additional clinical data may influence confidence in durability and retreatment strategy
Filed Aug 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results announced for quarter ended June 30, 2026
  • Full financial results and management commentary available in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Phase 3 AURORA MG data expected 1Q27, with BLA filing planned for mid-2027; primary value inflection for Descartes-08
  • Cash, equivalents and restricted cash $149.3M, supporting planned operations into 2028 alongside four expected clinical readouts

AI summaries of RNAC 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for RNAC

Don't miss the next RNAC filing

  • Alerts as it files. A push when RNAC files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut RNAC, by share count.
  • Ask anything. An AI agent that reads every RNAC filing and answers with sources.

RNAC alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Hoge ElizabethMApr 2, 2026-
Hoge ElizabethMApr 2, 2026-
Kalayoglu MuratMApr 2, 2026-
Kalayoglu MuratMApr 2, 2026-
Singer MichaelGMar 13, 2026-
Miljkovic MilosSellJan 6, 2026$6.82
Brunn CarstenSellJan 6, 2026$6.82
Davis BlaineSellJan 6, 2026$6.82

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$38.3M$400K
Operating Income--$43.9M-$143.4M
Net Income-$219.7M-$77.4M-$130.3M
Op. Margin--114.7%-35851.3%
Net Margin--202.3%-32575.5%
Balance Sheet
Total Assets$305.1M$435.0M$296.4M
Equity--$6.8M-$126.2M
ROE-1138.3%103.2%
Per Share
EPS$-1.66$-4.49$-5.02
Cash Flow
Operating CF--$23.7M-$73.9M
CapEx$206K$9.1M$5.5M

Source: XBRL data in Cartesian Therapeutics, Inc. (RNAC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate RNAC share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
RNAC shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202621$21.9M
Q2 202621$36.0M
Q1 202619$18.2M
Q4 202517$24.4M
Q3 202513$38.9M
Q2 202513$41.5M
Q1 202513$46.9M
Q4 202410$62.5M
Position changes: Q2 2026 → Q3 2026
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 127 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

RNAC filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
8-KSep 29, 2026Analysis-
SC 13GAug 13, 2026-
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
8-KJun 17, 2026Analysis-
8-KJun 9, 2026Analysis
8-KMay 26, 2026Analysis
8-KApr 30, 2026Analysis-
10-QApr 30, 2026Analysis
4Apr 6, 2026--
4Apr 6, 2026--
8-KMar 30, 2026--
4Mar 13, 2026--
SC 13GMar 13, 2026-
10-KMar 9, 2026Analysis
8-KMar 9, 2026Analysis-
8-KJan 9, 2026-
4Jan 8, 2026-
4Jan 8, 2026-
4Jan 8, 2026-
4Jan 6, 2026-
4Jan 6, 2026-
4Jan 6, 2026-

Related Health Care companies

All Health Care →

RNAC SEC filings: frequently asked questions

Which institutions hold RNAC stock?

As of September 30, 2026, the largest Cartesian Therapeutics, Inc. (RNAC) holders among the 13F filers tracked by SignalX were BlackRock ($5.8 million), Vanguard Capital Management LLC ($4.0 million), Two Sigma Investments ($2.6 million), AQR Capital Management ($2.1 million), State Street Corp ($1.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was RNAC's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Cartesian Therapeutics, Inc. (RNAC) reported revenue of $400,000 (down 99.0% from FY2024) and a net loss of $130.3 million. Diluted EPS was -$5.02. The figures come from the XBRL data in the 10-K.

What are the main risks in RNAC's latest 10-K?

In the 10-K filed March 9, 2026, Cartesian Therapeutics, Inc. (RNAC) flagged: FDA investigation of T-cell malignancy risk for CAR-T therapies including Descartes-08, with potential for boxed warnings or REMS requirements in 2024-2025. Geopolitical conflict risks delaying patient enrollment in clinical trials, impacting multinational trial sites and timelines. (AI summary of the Risk Factors section.)

What did RNAC report in its latest 8-K?

Cartesian Therapeutics, Inc. (RNAC) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest RNAC SEC filings?

Cartesian Therapeutics, Inc. (RNAC) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on April 6, 2026.

What is RNAC's SEC CIK number?

Cartesian Therapeutics, Inc. (RNAC)'s SEC Central Index Key (CIK) is 1453687. EDGAR lists every RNAC filing under that number.

Ask anything about RNAC

The research agent reads RNAC's filings, financials, insider trades and 13F holders, then answers with sources.